Breast Cancer Oncotype DX & Oncotype DX DCIS Score

The new Breast Cancer Oncotype DX® Recurrence Score Test and Oncotype DX® DCIS Score™  will begin at the start of 2018.
One year ago the company that developed the test, Genomic Health Inc, released at least 14 years of study that supports the use of Oncotype DX for patients already diagnosed and newly diagnosed with breast cancer.

The new scoring scale will guide the current staging scheme that is used to plan a patient’s treatment and prognosis and may, in many cases, mean a “down staging” for some women with a low Recurrence Score.
Learn more here.